Pyoderma Gangrenosum Clinical Trials

Find Pyoderma Gangrenosum Clinical Trials Near You

A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This study was designed to assess the therapeutic efficacy and safety of SHR-1139 Injection in adult patients with ulcerative pyoderma gangrenosum.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Male or female, age ≥ 18 years old at the time of signing the informed consent form (ICF).

• Diagnosed with ulcerative PG during screening, and requiring systemic treatment as assessed by the investigator.

• At screening and baseline, there is at least one measurable PG ulcer. If a subject has more than one PG ulcer, the investigator will select the target PG ulcer.

• Subjects voluntarily sign informed consent form (ICF) prior to the commencement of any procedures related to the study, are able to communicate smoothly with the investigator, understand and are willing to complete the study in strict compliance with the requirements of this clinical study protocol.

• Adequate organ and bone marrow function.

• Female subjects of childbearing potential or male subjects whose partners are females of childbearing potential shall have no plans for childbearing, sperm/egg donation from the time of signing the informed consent form until 72 weeks after the last dose, and shall voluntarily adopt effective contraceptive measures (including their partners). Female subjects must have a negative pregnancy test result during the screening period and before randomization and drug administration, and must not be breastfeeding.

Locations
Other Locations
China
Dermatology Hospital Affiliated to Shandong First Medical University
RECRUITING
Jinan
Contact Information
Primary
Furen Zhang
splcsy@126.com
15854179852
Time Frame
Start Date: 2026-01-29
Estimated Completion Date: 2028-06
Participants
Target number of participants: 10
Treatments
Experimental: SHR-1139 injection group
Related Therapeutic Areas
Sponsors
Leads: Shandong First Medical University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.